The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Memantine Hydrochloride Extended-Release Capsule Market Research Report 2024
Synopsis
Memantine hydrochloride extended-release capsules are a medication used in the treatment of Alzheimer's disease. The active ingredient in these capsules is memantine hydrochloride, which is a type of medication known as an N-methyl-D-aspartate (NMDA) receptor antagonist. Alzheimer's disease is a progressive neurodegenerative disorder that affects memory, thinking, and behavior. It is characterized by the accumulation of a protein called beta-amyloid in the brain, leading to the death of nerve cells and the disruption of normal brain function.
Global Memantine Hydrochloride Extended-Release Capsule market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Memantine Hydrochloride Extended-Release Capsule market research.
Key companies engaged in the Memantine Hydrochloride Extended-Release Capsule industry include Lundbeck, Allergan, Novartis, Lupin Ltd, Huahai Pharmaceutical, Daiichi Sankyo Company Limited, Rottendorf Pharma GmbH, Polygen Pharms and Macleods Pharms, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Memantine Hydrochloride Extended-Release Capsule were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Memantine Hydrochloride Extended-Release Capsule market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Memantine Hydrochloride Extended-Release Capsule market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Lundbeck
Allergan
Novartis
Lupin Ltd
Huahai Pharmaceutical
Daiichi Sankyo Company Limited
Rottendorf Pharma GmbH
Polygen Pharms
Macleods Pharms
Amneal Pharms
Apeloa Pharmaceutical
HUMANWELL GROUP
Eisai Co
Ono Pharmaceutical
Slate Run
Easton Bio Pharmaceuticals
Segment by Type
7mg
14mg
21mg
28mg
Others
Segment by Application
Home
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Memantine Hydrochloride Extended-Release Capsule report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Memantine hydrochloride extended-release capsules are a medication used in the treatment of Alzheimer's disease. The active ingredient in these capsules is memantine hydrochloride, which is a type of medication known as an N-methyl-D-aspartate (NMDA) receptor antagonist. Alzheimer's disease is a progressive neurodegenerative disorder that affects memory, thinking, and behavior. It is characterized by the accumulation of a protein called beta-amyloid in the brain, leading to the death of nerve cells and the disruption of normal brain function.
Global Memantine Hydrochloride Extended-Release Capsule market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Memantine Hydrochloride Extended-Release Capsule market research.
Key companies engaged in the Memantine Hydrochloride Extended-Release Capsule industry include Lundbeck, Allergan, Novartis, Lupin Ltd, Huahai Pharmaceutical, Daiichi Sankyo Company Limited, Rottendorf Pharma GmbH, Polygen Pharms and Macleods Pharms, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Memantine Hydrochloride Extended-Release Capsule were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Memantine Hydrochloride Extended-Release Capsule market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Memantine Hydrochloride Extended-Release Capsule market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Lundbeck
Allergan
Novartis
Lupin Ltd
Huahai Pharmaceutical
Daiichi Sankyo Company Limited
Rottendorf Pharma GmbH
Polygen Pharms
Macleods Pharms
Amneal Pharms
Apeloa Pharmaceutical
HUMANWELL GROUP
Eisai Co
Ono Pharmaceutical
Slate Run
Easton Bio Pharmaceuticals
Segment by Type
7mg
14mg
21mg
28mg
Others
Segment by Application
Home
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Memantine Hydrochloride Extended-Release Capsule report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Memantine Hydrochloride Extended-Release Capsule Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 7mg
1.2.3 14mg
1.2.4 21mg
1.2.5 28mg
1.2.6 Others
1.3 Market by Application
1.3.1 Global Memantine Hydrochloride Extended-Release Capsule Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Home
1.3.3 Hospital
1.3.4 Clinic
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Memantine Hydrochloride Extended-Release Capsule Market Perspective (2018-2029)
2.2 Memantine Hydrochloride Extended-Release Capsule Growth Trends by Region
2.2.1 Global Memantine Hydrochloride Extended-Release Capsule Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Memantine Hydrochloride Extended-Release Capsule Historic Market Size by Region (2018-2023)
2.2.3 Memantine Hydrochloride Extended-Release Capsule Forecasted Market Size by Region (2024-2029)
2.3 Memantine Hydrochloride Extended-Release Capsule Market Dynamics
2.3.1 Memantine Hydrochloride Extended-Release Capsule Industry Trends
2.3.2 Memantine Hydrochloride Extended-Release Capsule Market Drivers
2.3.3 Memantine Hydrochloride Extended-Release Capsule Market Challenges
2.3.4 Memantine Hydrochloride Extended-Release Capsule Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Memantine Hydrochloride Extended-Release Capsule Players by Revenue
3.1.1 Global Top Memantine Hydrochloride Extended-Release Capsule Players by Revenue (2018-2023)
3.1.2 Global Memantine Hydrochloride Extended-Release Capsule Revenue Market Share by Players (2018-2023)
3.2 Global Memantine Hydrochloride Extended-Release Capsule Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Memantine Hydrochloride Extended-Release Capsule Revenue
3.4 Global Memantine Hydrochloride Extended-Release Capsule Market Concentration Ratio
3.4.1 Global Memantine Hydrochloride Extended-Release Capsule Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Memantine Hydrochloride Extended-Release Capsule Revenue in 2022
3.5 Memantine Hydrochloride Extended-Release Capsule Key Players Head office and Area Served
3.6 Key Players Memantine Hydrochloride Extended-Release Capsule Product Solution and Service
3.7 Date of Enter into Memantine Hydrochloride Extended-Release Capsule Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Memantine Hydrochloride Extended-Release Capsule Breakdown Data by Type
4.1 Global Memantine Hydrochloride Extended-Release Capsule Historic Market Size by Type (2018-2023)
4.2 Global Memantine Hydrochloride Extended-Release Capsule Forecasted Market Size by Type (2024-2029)
5 Memantine Hydrochloride Extended-Release Capsule Breakdown Data by Application
5.1 Global Memantine Hydrochloride Extended-Release Capsule Historic Market Size by Application (2018-2023)
5.2 Global Memantine Hydrochloride Extended-Release Capsule Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Memantine Hydrochloride Extended-Release Capsule Market Size (2018-2029)
6.2 North America Memantine Hydrochloride Extended-Release Capsule Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Memantine Hydrochloride Extended-Release Capsule Market Size by Country (2018-2023)
6.4 North America Memantine Hydrochloride Extended-Release Capsule Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Memantine Hydrochloride Extended-Release Capsule Market Size (2018-2029)
7.2 Europe Memantine Hydrochloride Extended-Release Capsule Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Memantine Hydrochloride Extended-Release Capsule Market Size by Country (2018-2023)
7.4 Europe Memantine Hydrochloride Extended-Release Capsule Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Memantine Hydrochloride Extended-Release Capsule Market Size (2018-2029)
8.2 Asia-Pacific Memantine Hydrochloride Extended-Release Capsule Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Memantine Hydrochloride Extended-Release Capsule Market Size by Region (2018-2023)
8.4 Asia-Pacific Memantine Hydrochloride Extended-Release Capsule Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Memantine Hydrochloride Extended-Release Capsule Market Size (2018-2029)
9.2 Latin America Memantine Hydrochloride Extended-Release Capsule Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Memantine Hydrochloride Extended-Release Capsule Market Size by Country (2018-2023)
9.4 Latin America Memantine Hydrochloride Extended-Release Capsule Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Memantine Hydrochloride Extended-Release Capsule Market Size (2018-2029)
10.2 Middle East & Africa Memantine Hydrochloride Extended-Release Capsule Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Memantine Hydrochloride Extended-Release Capsule Market Size by Country (2018-2023)
10.4 Middle East & Africa Memantine Hydrochloride Extended-Release Capsule Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lundbeck
11.1.1 Lundbeck Company Detail
11.1.2 Lundbeck Business Overview
11.1.3 Lundbeck Memantine Hydrochloride Extended-Release Capsule Introduction
11.1.4 Lundbeck Revenue in Memantine Hydrochloride Extended-Release Capsule Business (2018-2023)
11.1.5 Lundbeck Recent Development
11.2 Allergan
11.2.1 Allergan Company Detail
11.2.2 Allergan Business Overview
11.2.3 Allergan Memantine Hydrochloride Extended-Release Capsule Introduction
11.2.4 Allergan Revenue in Memantine Hydrochloride Extended-Release Capsule Business (2018-2023)
11.2.5 Allergan Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Memantine Hydrochloride Extended-Release Capsule Introduction
11.3.4 Novartis Revenue in Memantine Hydrochloride Extended-Release Capsule Business (2018-2023)
11.3.5 Novartis Recent Development
11.4 Lupin Ltd
11.4.1 Lupin Ltd Company Detail
11.4.2 Lupin Ltd Business Overview
11.4.3 Lupin Ltd Memantine Hydrochloride Extended-Release Capsule Introduction
11.4.4 Lupin Ltd Revenue in Memantine Hydrochloride Extended-Release Capsule Business (2018-2023)
11.4.5 Lupin Ltd Recent Development
11.5 Huahai Pharmaceutical
11.5.1 Huahai Pharmaceutical Company Detail
11.5.2 Huahai Pharmaceutical Business Overview
11.5.3 Huahai Pharmaceutical Memantine Hydrochloride Extended-Release Capsule Introduction
11.5.4 Huahai Pharmaceutical Revenue in Memantine Hydrochloride Extended-Release Capsule Business (2018-2023)
11.5.5 Huahai Pharmaceutical Recent Development
11.6 Daiichi Sankyo Company Limited
11.6.1 Daiichi Sankyo Company Limited Company Detail
11.6.2 Daiichi Sankyo Company Limited Business Overview
11.6.3 Daiichi Sankyo Company Limited Memantine Hydrochloride Extended-Release Capsule Introduction
11.6.4 Daiichi Sankyo Company Limited Revenue in Memantine Hydrochloride Extended-Release Capsule Business (2018-2023)
11.6.5 Daiichi Sankyo Company Limited Recent Development
11.7 Rottendorf Pharma GmbH
11.7.1 Rottendorf Pharma GmbH Company Detail
11.7.2 Rottendorf Pharma GmbH Business Overview
11.7.3 Rottendorf Pharma GmbH Memantine Hydrochloride Extended-Release Capsule Introduction
11.7.4 Rottendorf Pharma GmbH Revenue in Memantine Hydrochloride Extended-Release Capsule Business (2018-2023)
11.7.5 Rottendorf Pharma GmbH Recent Development
11.8 Polygen Pharms
11.8.1 Polygen Pharms Company Detail
11.8.2 Polygen Pharms Business Overview
11.8.3 Polygen Pharms Memantine Hydrochloride Extended-Release Capsule Introduction
11.8.4 Polygen Pharms Revenue in Memantine Hydrochloride Extended-Release Capsule Business (2018-2023)
11.8.5 Polygen Pharms Recent Development
11.9 Macleods Pharms
11.9.1 Macleods Pharms Company Detail
11.9.2 Macleods Pharms Business Overview
11.9.3 Macleods Pharms Memantine Hydrochloride Extended-Release Capsule Introduction
11.9.4 Macleods Pharms Revenue in Memantine Hydrochloride Extended-Release Capsule Business (2018-2023)
11.9.5 Macleods Pharms Recent Development
11.10 Amneal Pharms
11.10.1 Amneal Pharms Company Detail
11.10.2 Amneal Pharms Business Overview
11.10.3 Amneal Pharms Memantine Hydrochloride Extended-Release Capsule Introduction
11.10.4 Amneal Pharms Revenue in Memantine Hydrochloride Extended-Release Capsule Business (2018-2023)
11.10.5 Amneal Pharms Recent Development
11.11 Apeloa Pharmaceutical
11.11.1 Apeloa Pharmaceutical Company Detail
11.11.2 Apeloa Pharmaceutical Business Overview
11.11.3 Apeloa Pharmaceutical Memantine Hydrochloride Extended-Release Capsule Introduction
11.11.4 Apeloa Pharmaceutical Revenue in Memantine Hydrochloride Extended-Release Capsule Business (2018-2023)
11.11.5 Apeloa Pharmaceutical Recent Development
11.12 HUMANWELL GROUP
11.12.1 HUMANWELL GROUP Company Detail
11.12.2 HUMANWELL GROUP Business Overview
11.12.3 HUMANWELL GROUP Memantine Hydrochloride Extended-Release Capsule Introduction
11.12.4 HUMANWELL GROUP Revenue in Memantine Hydrochloride Extended-Release Capsule Business (2018-2023)
11.12.5 HUMANWELL GROUP Recent Development
11.13 Eisai Co
11.13.1 Eisai Co Company Detail
11.13.2 Eisai Co Business Overview
11.13.3 Eisai Co Memantine Hydrochloride Extended-Release Capsule Introduction
11.13.4 Eisai Co Revenue in Memantine Hydrochloride Extended-Release Capsule Business (2018-2023)
11.13.5 Eisai Co Recent Development
11.14 Ono Pharmaceutical
11.14.1 Ono Pharmaceutical Company Detail
11.14.2 Ono Pharmaceutical Business Overview
11.14.3 Ono Pharmaceutical Memantine Hydrochloride Extended-Release Capsule Introduction
11.14.4 Ono Pharmaceutical Revenue in Memantine Hydrochloride Extended-Release Capsule Business (2018-2023)
11.14.5 Ono Pharmaceutical Recent Development
11.15 Slate Run
11.15.1 Slate Run Company Detail
11.15.2 Slate Run Business Overview
11.15.3 Slate Run Memantine Hydrochloride Extended-Release Capsule Introduction
11.15.4 Slate Run Revenue in Memantine Hydrochloride Extended-Release Capsule Business (2018-2023)
11.15.5 Slate Run Recent Development
11.16 Easton Bio Pharmaceuticals
11.16.1 Easton Bio Pharmaceuticals Company Detail
11.16.2 Easton Bio Pharmaceuticals Business Overview
11.16.3 Easton Bio Pharmaceuticals Memantine Hydrochloride Extended-Release Capsule Introduction
11.16.4 Easton Bio Pharmaceuticals Revenue in Memantine Hydrochloride Extended-Release Capsule Business (2018-2023)
11.16.5 Easton Bio Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
